Skip to NavigationSkip to content

peanut allergy

Aimmune's peanut allergy candidate hits main endpoint at Phase 3

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial of its kind, proving that around two-thirds of patients were are able to tolerate at least 600mg of peanut protein - equal to about two average peanut kernels – after taking the drug.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches